RSA and Swissbit Announce New Phishing-Resistant Authentication Solution for Security-First Industries
RSA, the security-first identity leader and Swissbit, a long-standing leading expert and manufacturer of storage, security, and embedded IoT solutions, announced a new, next-generation hardware authenticator series today designed to protect highly regulated industries.
The RSA iShield Key 2 series, powered by Swissbit, will provide financial services, energy, healthcare, and other highly regulated organizations with the highest-level of phishing-resistant, passwordless authentication needed to simplify credential management and drive toward Zero Architecture (ZTA). Optimized for the RSA cloud identity and access management (IAM) platform, RSA® ID Plus, the RSA iShield Key 2 series offers premiere security and unparalleled flexibility. The RSA iShield Key 2 series is available for order now and will ship Q4 2024.
“The worst attacks demand the best defenses. That’s why security-first leaders have trusted RSA for decades to defend them from the most damaging cyberattacks. By working with a leader like Swissbit, we can expand our unified identity platform and deliver innovations like the RSA iShield Key 2 that provide a broader range of capabilities, all fortified by the security depth unique to RSA,” said Rohit Ghai, CEO, RSA.
“To secure their operations and stay operational, leaders in finance, healthcare, energy, and manufacturing need strong, phishing-resistant capabilities built to enable users and resist modern attacks. Together, Swissbit and RSA are bringing those innovations to the private sector organizations that need them most,” said Silvio Muschter, CEO of Swissbit AG.
By offering the RSA iShield Key 2 series through ID Plus, RSA and Swissbit can bring organizations key benefits, including:
- Secure, phishing-resistant authentication: the RSA DS100, RSA Authenticator App, and the RSA iShield Key 2 series supports FIDO2, smart card, and OTP for legacy applications, providing multi-protocol multi-factor authentication (MFA) for a variety of users and use cases.
- FIPS 140-3 validated security: the RSA iShield Key 2 series provides the highest level of cryptographic protection and ensures that every organization’s infrastructure meets the most stringent cybersecurity requirements.
- Accelerating Zero Trust maturity: RSA ID Plus allows organizations to meet key ZTA requirements, including implementing centralized credential management and visibility over all access points.
- Single sign-on (SSO) and self-service capabilities: users can easily register, update, and manage their credentials with RSA ID Plus, minimizing costs on IT teams and accelerating productivity.
Availability and support
The RSA iShield Key 2 series, powered by Swissbit, is available for order now and will ship at the end of 2024. Both companies will support their customers with comprehensive training and support services to ensure smooth integration and implementation.
Resources:
About RSA
The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
About Swissbit
Swissbit AG is the leading European provider of storage, security and embedded IoT solutions for demanding applications. Swissbit combines its unique competencies in storage and embedded IoT technology with its advanced packaging know-how. This expertise allows our customers to reliably store and protect data in industrial, NetCom, automotive, medical and fiscal applications as well as across the Internet of Things (IoT). Swissbit develops and manufactures industrial-grade storage and security products “Made in Germany” with high reliability, long-term availability, and custom optimization. Swissbit was founded in 2001 and has offices in Switzerland, Germany, USA, Japan and Taiwan. For further information, please visit www.swissbit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001333919/en/
Contacts
Media contact:
teamrsa@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cybersecurity Teams Can’t Keep up With Growing Levels of Cyberattacks, New Research Reveals1.10.2024 14:00:00 EEST | Press release
Cybersecurity teams are under strain, as 61% of European cybersecurity professionals say that their organisation’s cybersecurity team is understaffed, and over half (52%) believe that their organisation’s cybersecurity budget is underfunded. That’s according to new research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust. Staff and funding struggles are having an impact on wellbeing as 68% feel that their role is more stressful now compared to five years ago, with 79% putting this down to the increasingly complex threat landscape. Two in five (41%) of respondents say they are experiencing more cyberattacks when compared to a year ago, and 29% think they are experiencing the same amount. But respondents don’t feel the number of attacks will be slowing down any time soon. Over half (58%) state it is likely their organisation will experience a cyberattack in the next year. This has increased by 6 percentage po
New Pharmanovia Study Results Reveal Chloral Hydrate Noticeably Improves Severe Insomnia Within Two Weeks1.10.2024 13:45:00 EEST | Press release
FOR MEDICINAL TRADE AND BUSINESS MEDIA ONLY Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises the lifecycle of established medicines, today announced positive topline results of its open label RESTORE trial in severe insomnia, in partnership with Lindus Health. A topline readout using patient-reported outcomes (PROs) has found that short-term use of chloral hydrate shows benefit in people with severe insomnia where it is interfering with normal daily life and when other therapies (behavioural and pharmacologic) have failed. The trial (NCT06053840) enrolled 100 adult patients who received chloral hydrate treatment over 14 days and came from primary and secondary care sites. Patients were closely monitored by a virtual team of secondary care sleep specialists, as part of the decentralised trial design, and were assessed for the safety, tolerability and identification of baseline characteristics, changes in sleep and quality of life outcomes.
TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal1.10.2024 11:46:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech focused on using its proprietary GMP compliant technology platform, C-Stem™, to develop life-saving cell therapies, today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009598667/en/ TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics) The potential of cell therapy for Parkinson’s Disease is well documented – dating back to pioneering studies in the 1980s using fetal cell transplants – and scientific progress over the last decades provides great hope for the future. The emergence of induced pluripotent cells (iPSCs) opened new pathways and solved one of the first ma
Datalec Precision Installations Appoints Peter Cole as Executive Vice President for APAC Region1.10.2024 11:35:00 EEST | Press release
Datalec Precision Installations (DPI), a provider of world-class data centre design, supply, build, and managed services delivering seamless and integrated end-to-end solutions for data centre operators, today announced the appointment of Peter Cole as Executive Vice President for the Asia-Pacific (APAC) region. Based in Singapore, Cole will spearhead DPI's expansion and strategic growth initiatives across APAC's dynamic data centre market, expected to nearly double to $150.59 billion by 2029. Bringing over four decades of experience in the electrotechnical and digital industry, Cole brings a wealth of expertise to his new role. He will oversee all aspects of DPI's APAC data centre business, including strategic planning, operations, and business development. "Peter's extensive experience and deep understanding of the APAC market make him the ideal leader to drive our growth in this critical region," said Danny Keeper, Group Director of DPI. "His proven track record in delivering large-
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells1.10.2024 11:30:00 EEST | Press release
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting agents that address patients’ unmet medical needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241001468319/en/ AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart) Focus on a promising target The new compound, AOP208, targets and blocks a protein on the surface of the cancer stem cell, the serotonin receptor 1B, which may prove to be critical to treat the root cause of the disease. The compound is given orally and was designed and initially
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom